Momenta Pharmaceuticals, Inc. (MNTA)
Baxter International Inc. Collaboration Conference Call
December 23, 2011 10:00 am ET
Beverly Holley – Director, Investor Relations
Craig A. Wheeler – President and Chief Executive Officer
Richard P. Shea – Chief Financial Officer
Ganesh Venkataraman Ph.D. – Senior Vice President, Chief Scientific Officer
Ritu Baral – Canaccord Genuity
Sapna Srivastava – Goldman Sachs
Ami Fadia – UBS
Eric Schmidt – Cowen & Company
Bret Holley – Oppenheimer & Co.
Sumant Kulkarni – Bank of America/Merrill Lynch
Joseph P. Schwartz – Leerink Swann & Company
Duane Nash – Wedbush Securities
Alan Sonnenfeld – Bernstein
Avik Roy – Monness, Crespi, Hardt
Rajeev Jashnani – UBS Investment Bank
Frank Rango – Purchase Capital Management
Good day, ladies and gentlemen, and welcome to the Momenta Biosimilars Update. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. (Operator Instructions) As a reminder, this conference call is being recorded.
I would now like to introduce your host for today's conference, Beverly Holley, Director of Investor Relations.
Thank you, and good morning. I want to welcome all of you to Momenta's conference call to discuss our recently-announced follow-on biologics collaboration with Baxter. With me on the call today with prepared remarks is Craig Wheeler, our President and Chief Executive Officer. Also present are Rick Shea, our CFO, and Ganesh Venkataraman, our Chief Scientific Officer. Following our remarks, we will open the call to questions.